Khloud A Elsharawy1,2, Maryam Althobiti1,3, Omar J Mohammed1, Abrar I Aljohani1, Michael S Toss1, Andrew R Green1, Emad A Rakha4,5. 1. Nottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham, UK. 2. Faculty of Science, Damietta University, Damietta, Egypt. 3. Department of Clinical Laboratory Science, College of Applied Medical Science, Shaqra University, Shaqra, Saudi Arabia. 4. Nottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham, UK. Emad.rakha@nuh.nhs.uk. 5. Division of Cancer and Stem Cell, University of Nottingham, City Hospital Campus, Hucknall Road, Nottingham, NG5 1PB, UK. Emad.rakha@nuh.nhs.uk.
Abstract
PURPOSE: Nucleolar protein 10 (NOP10) is required for ribosome biogenesis and telomere maintenance and plays a key role in carcinogenesis. This study aims to evaluate the clinical and prognostic significance of NOP10 in breast cancer (BC). METHODS: NOP10 expression was assessed at mRNA level employing the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) (n = 1980) and Cancer Genome Atlas (TCGA) BC cohorts (n = 854). Protein expression was evaluated on tissue microarray of a large BC cohort (n = 1081) using immunohistochemistry. The correlation between NOP10 expression, clinicopathological parameters and patient outcome was assessed. RESULTS: NOP10 expression was detected in the nucleus and nucleolus of the tumour cells. At the transcriptomic and proteomic levels, NOP10 was significantly associated with aggressive BC features including high tumour grade, high nucleolar score and poor Nottingham Prognostic Index. High NOP10 protein expression was an independent predictor of poor outcome in the whole cohort and in triple-negative BC (TNBC) class (p = 0.002 & p = 0.014, respectively). In chemotherapy- treated patients, high NOP10 protein expression was significantly associated with shorter survival (p = 0.03) and was predictive of higher risk of death (p = 0.028) and development of distant metastasis (p = 0.02) independent of tumour size, nodal stage and tumour grade. CONCLUSION: High NOP10 expression is a poor prognostic biomarker in BC and its expression can help in predicting chemotherapy resistance. Functional assessments are necessary to decipher the underlying mechanisms and to reveal its potential therapeutic values in various BC subtypes especially in the aggressive TNBC class.
PURPOSE: Nucleolar protein 10 (NOP10) is required for ribosome biogenesis and telomere maintenance and plays a key role in carcinogenesis. This study aims to evaluate the clinical and prognostic significance of NOP10 in breast cancer (BC). METHODS: NOP10 expression was assessed at mRNA level employing the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) (n = 1980) and Cancer Genome Atlas (TCGA) BC cohorts (n = 854). Protein expression was evaluated on tissue microarray of a large BC cohort (n = 1081) using immunohistochemistry. The correlation between NOP10 expression, clinicopathological parameters and patient outcome was assessed. RESULTS: NOP10 expression was detected in the nucleus and nucleolus of the tumour cells. At the transcriptomic and proteomic levels, NOP10 was significantly associated with aggressive BC features including high tumour grade, high nucleolar score and poor Nottingham Prognostic Index. High NOP10 protein expression was an independent predictor of poor outcome in the whole cohort and in triple-negative BC (TNBC) class (p = 0.002 & p = 0.014, respectively). In chemotherapy- treated patients, high NOP10 protein expression was significantly associated with shorter survival (p = 0.03) and was predictive of higher risk of death (p = 0.028) and development of distant metastasis (p = 0.02) independent of tumour size, nodal stage and tumour grade. CONCLUSION: High NOP10 expression is a poor prognostic biomarker in BC and its expression can help in predicting chemotherapy resistance. Functional assessments are necessary to decipher the underlying mechanisms and to reveal its potential therapeutic values in various BC subtypes especially in the aggressive TNBC class.
Entities:
Keywords:
Invasive breast cancer; NOP10; Nucleoli; Prognosis
Authors: Kristoffer von Stedingk; Jan Koster; Marta Piqueras; Rosa Noguera; Samuel Navarro; Sven Påhlman; Rogier Versteeg; Ingrid Ora; David Gisselsson; David Lindgren; Håkan Axelson Journal: Transl Oncol Date: 2013-08-01 Impact factor: 4.243
Authors: Thomas C Putti; Dalia M Abd El-Rehim; Emad A Rakha; Claire E Paish; Andrew H S Lee; Sarah E Pinder; Ian O Ellis Journal: Mod Pathol Date: 2005-01 Impact factor: 7.842
Authors: Emad A Rakha; Devika Agarwal; Andrew R Green; Ibraheem Ashankyty; Ian O Ellis; Graham Ball; Mohammed A Alaskandarany Journal: Histopathology Date: 2016-12-28 Impact factor: 5.087
Authors: María Monteagudo; Paula Martínez; Luis J Leandro-García; Ángel M Martínez-Montes; Bruna Calsina; Marta Pulgarín-Alfaro; Alberto Díaz-Talavera; Sara Mellid; Rocío Letón; Eduardo Gil; Manuel Pérez-Martínez; Diego Megías; Raúl Torres-Ruiz; Sandra Rodriguez-Perales; Patricia González; Eduardo Caleiras; Scherezade Jiménez-Villa; Giovanna Roncador; Cristina Álvarez-Escolá; Rita M Regojo; María Calatayud; Sonsoles Guadalix; Maria Currás-Freixes; Elena Rapizzi; Letizia Canu; Svenja Nölting; Hanna Remde; Martin Fassnacht; Nicole Bechmann; Graeme Eisenhofer; Massimo Mannelli; Felix Beuschlein; Marcus Quinkler; Cristina Rodríguez-Antona; Alberto Cascón; María A Blasco; Cristina Montero-Conde; Mercedes Robledo Journal: Cancers (Basel) Date: 2021-09-23 Impact factor: 6.575